title: Unusual persistence in healthy volunteers and ill patients of hyperimmune immunoglobulin directed against multiple Pseudomonas O-chain and Klebsiella serotypes after intravenous infusion.
abstract: Persistence of intravenous (i.v.) hyperimmune immunoglobulin (100 mg/kg) directed against clinically predominant serotypes of Pseudomonas and Klebsiella in ill, febrile patients was compared to healthy volunteers to determine if ill patients have a decreased Ig half-life resulting in an increased immunoglobulin requirement. Type-specific antibodies were measured by ELISA for 83 days in eight healthy volunteers and for 35 days in eight ill patients with surgical complications or hematologic malignancy. Mean values and fold rises of antibody concentrations for the two groups were above preinfusion values at 35 days. The antibody fold rises in patients and in healthy volunteers were similar. Type-specific antibody levels in some patients increased after illness coincident with elevation of total immunoglobulins. We conclude that the duration of potentially therapeutic levels of infused type-specific hyperimmune immunoglobulin may persist for a longer period of time than what has been measured for total immunoglobulin. While the mechanism of this persistence remains to be characterized, the possibility of type-specific antibody synthesis induced by immunoglobulin administration must be considered.
authors.affiliation: Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, DC 20307, USA. mcclain@medimmune.com
authors.forename: J B
authors.initials: JB
authors.lastname: McClain
authors.forename: R
authors.initials: R
authors.lastname: Edelman
authors.forename: M
authors.initials: M
authors.lastname: Shmuklarsky
authors.forename: J
authors.initials: J
authors.lastname: Que
authors.forename: S J
authors.initials: SJ
authors.lastname: Cryz
authors.forename: A S
authors.initials: AS
authors.lastname: Cross
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D006207:Half-Life; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000097:blood*; D007262:Infusions, Intravenous; D007709:Klebsiella / Q000145:classification / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D019081:O Antigens / Q000276:immunology; D011549:Pseudomonas / Q000145:classification / Q000276:immunology*; D012703:Serotyping
chemical_list: D007136:Immunoglobulins; D019081:O Antigens